Journal Reviews
Ten-year experience with intracameral chemotherapy for aqueous seeding in retinoblastoma: long-term efficacy, safety and toxicity
This is a retrospective review of all consecutive patients with primary (n=4) or secondary non-iatrogenic (n=16) aqueous seeding (AS) treated by intracameral chemotherapy (ICC) in Lausanne between 2011 and 2020 with a minimum follow-up of one year. Aqueous seeding control...
Retinoblastoma mortality associations with choroidal and optic nerve invasion
The authors present a retrospective cohort study. Data was extracted from the National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) database, based in the US and founded in 1973. Cases of retinoblastoma were extracted using the inclusion criteria of...
Histopathology-guided management of ocular surface squamous neoplasia (OSSN) with corneal stromal or scleral invasion using ruthenium-106 plaque brachytherapy
This is a retrospective interventional consecutive case series of 42 eyes of 42 patients with OSSN with histopathologically proven corneal stromal and / or scleral invasion following excision biopsy. The mean tumour basal diameter was 9.3mm and thickness of 3.1mm...
Germline testing for uveal melanoma
The authors present a study of 114 consecutive patients presenting with uveal melanoma. Between 1 December 2019 and 1 November 2021 all patients over 18-years-old presenting to their centre with uveal melanoma were offered germline testing for variants in BAP1,...
Cutaneous malignant melanoma metastasis to pseudophakic lens
Metastases to the eye and orbit are rare and intraocular cutaneous malignant melanoma metastasis (ICMM) is exceedingly rare, representing around 5%. There have only been three previous cases of ICMM to the lens in the literature, all of which presented...
Recurrent sebaceous gland carcinoma
In this retrospective case review study, authors report their outcomes in management of recurrent sebaceous gland carcinoma (SGC) and propose a graded protocol to manage these entities. All consecutive cases of SGC from January 2004 to December 2017 at the...
Online retinoblastoma surveillance tool
Given the vision and life-threatening course of retinoblastoma (RB), it has become a significant heritable childhood cancer to screen for. To recommend surveillance, risk must be estimated and genetic testing plays a vital role. However, genetic tests vary based on...
Ocular adnexal marginal zone b-cell lymphoma
This is a multicentre retrospective study of seven eye centres of 689 patients with ocular adnexal extranodal marginal zone b-cell lymphoma (OA-EMZL). The median follow-up time was 42 months and the median age was 62 years. Fifty-five percent were women;...
Quality of life concerns after uveal melanoma diagnosis
The authors sought to investigate factors associated with Quality Of Life (QOL) after initial diagnosis of uveal melanoma (UM) using prospectively collected data between September 2011-May 2016. They included 201 participants referred for radiotherapy after UM diagnosis by an ophthalmic...
Practice patterns of uveal melanoma management with Iodine-125 brachytherapy
With the 2006 Collaborative Ocular Melanoma Study Group (COMS) study demonstrating no difference in survival outcomes for participants randomised to either iodine-125 brachytherapy or enucleation, the majority of primary uveal melanomas in the United States are now treated with brachytherapy....
Episcleral brachytherapy (EB) for retinoblastoma (RB)
This retrospective study consisted of 11 eyes treated either with Iodine (I) -125 or Ruthenium (R) -106EB with a mean apical dose of 44Gy. There were five in group B (46%), three in group C (27%) and three in group...
A prospective trial of adjuvant therapy for high-risk melanoma
Patients diagnosed with iris, ciliary body or choroidal melanoma of high-risk tumour cytogenetics (monosomy 3>/= 20% of cells), were treated with adjuvant low-dose dacarbacine (DTIC) and interferon –alpha-2b (IFNA-2b), following primary treatment (enucleation, brachytherapy or resection). DTIC was given intravenously...